Trial · NCT04603495
Adverse events328
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 328
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anaemia | Blood and lymphatic system disorders | Pelabresib + Ruxolitinib (Experimental Arm) | 90 | 212 | |
| other | Anaemia | Blood and lymphatic system disorders | Placebo + Ruxolitinib (Control Arm) | 116 | 214 | |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Pelabresib + Ruxolitinib (Experimental Arm) | 68 | 212 | |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Placebo + Ruxolitinib (Control Arm) | 50 | 214 | |
| other | Constipation | Gastrointestinal disorders | Pelabresib + Ruxolitinib (Experimental Arm) | 39 | 212 | |
| other | Constipation | Gastrointestinal disorders | Placebo + Ruxolitinib (Control Arm) | 52 | 214 | |
| other | Diarrhoea | Gastrointestinal disorders | Pelabresib + Ruxolitinib (Experimental Arm) | 49 | 212 | |
| other | Diarrhoea | Gastrointestinal disorders | Placebo + Ruxolitinib (Control Arm) | 39 | 214 | |
| other | Nausea | Gastrointestinal disorders | Pelabresib + Ruxolitinib (Experimental Arm) | 30 | 212 | |
| other | Nausea | Gastrointestinal disorders | Placebo + Ruxolitinib (Control Arm) | 32 | 214 | |
| other | Abdominal Pain Upper | Gastrointestinal disorders | Pelabresib + Ruxolitinib (Experimental Arm) | 17 | 212 | |
| other | Abdominal Pain Upper | Gastrointestinal disorders | Placebo + Ruxolitinib (Control Arm) | 14 | 214 | |
| other | Vomiting | Gastrointestinal disorders | Pelabresib + Ruxolitinib (Experimental Arm) | 15 | 212 | |
| other | Vomiting | Gastrointestinal disorders | Placebo + Ruxolitinib (Control Arm) | 16 | 214 | |
| other | Abdominal Pain | Gastrointestinal disorders | Pelabresib + Ruxolitinib (Experimental Arm) | 8 | 212 | |
| other | Abdominal Pain | Gastrointestinal disorders | Placebo + Ruxolitinib (Control Arm) | 19 | 214 | |
| other | Fatigue | General disorders | Pelabresib + Ruxolitinib (Experimental Arm) | 25 | 212 | |
| other | Fatigue | General disorders | Placebo + Ruxolitinib (Control Arm) | 34 | 214 | |
| other | Asthenia | General disorders | Pelabresib + Ruxolitinib (Experimental Arm) | 25 | 212 | |
| other | Asthenia | General disorders | Placebo + Ruxolitinib (Control Arm) | 30 | 214 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04603495/events